Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)
Clinical trial NCT04963088 · COMPLETED
Trial details
- NCT number
- NCT04963088
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-06
- Primary completion
- 2024-03-15
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.